09:21 AM EDT, 05/28/2024 (MT Newswires) -- Health care stocks were mixed pre-bell Tuesday as the Health Care Select Sector SPDR Fund ( XLV ) was 0.2% lower and the iShares Biotechnology ETF ( IBB ) was recently inactive.

Insmed ( INSM ) was surging past 131% after saying its experimental drug, brensocatib, for the treatment of bronchiectasis lung disease, has met the primary endpoint in a late-stage study.

Calliditas Therapeutics ( CALT ) was rallying past 75% after saying its board of directors unanimously recommended that its shareholders accept an 11.16 billion Swedish krona ($1.06 billion) cash buyout offer from Asahi Kasei.

Agios Pharmaceuticals ( AGIO ) was up over 21% after saying it has agreed to sell its rights to a 15% royalty on the potential US net sales of Servier's vorasidenib to Royalty Pharma ( RPRX ) for $905 million.